跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 221 条关于
“Oligodendroglioma”
全部
221
临床试验
204
药物
0
机构
0
资讯
17
2年前
FDA Approves Vorasidenib (Voranigo) for IDH-Mutant Glioma, Developed from Duke Neurosurgeon's Discovery
2个月前
Vorasidenib Offers Targeted Treatment for IDH-Mutant Low-Grade Gliomas
2年前
FDA Approves Oncomine Dx Target Test as Companion Diagnostic for Vorasidenib in IDH-Mutant Glioma
去年
European Regulators Recommend Approval of Vorasidenib for IDH-Mutant Grade 2 Glioma
10个月前
Real-World Study Reveals Treatment Gap in IDH-Mutant Glioma, Supporting Need for Early Intervention
去年
FDA Approves Voranigo (Vorasidenib) as First Targeted Therapy for IDH-Mutant Glioma
去年
Vorasidenib Confirms Efficacy and Safety in IDH1/2-Mutant Diffuse Glioma
去年
Recent FDA Approvals and Clinical Trial Updates in Oncology Highlighted on OncLive On Air
去年
Eflornithine Combo Fails to Meet Primary Endpoint in Phase III Brain Cancer Trial
去年
CDSCO Panel Recommends Approval for Vorasidenib with Phase-III Waiver for IDH-Mutant Gliomas in India
第 1 页,共 2 页
上一页
下一页